Effect of Azacitidine Combined with Bcl-2 Inhibitor Venetoclax on Elderly Patients with Acute Myeloid Leukemia
Objective To analyse the effect of azacitidine combined with Bel-2 inhibitor venetoclax in the treatment of senile acute myeloid leukemia.Methods A total of 74 elderly patients with acute myeloid leukemia treated in Nanyang Central Hospital from December 2018 to December 2022 were extracted,and divided into study group and control group based on a coin toss,with 37 cases in each group.The control group was treated with DA regimen,and the study group was additionally treated with azacytoside and Bel-2 inhibitor Vinecra.Compared two groups of clinical effect and blood index(original proportion of bone marrow cells,platelet count,hemoglobin),immune function(T lymphocyte subsets CD3+,CD4+),interferon γ(IFN-γ),tumor necrosis factor alpha(TNF-α),adverse reactions and quality of life(QOL)score.Results The remission rate in the study group was higher than that in the control group(P＜0.05).After treatment,the original proportion of bone marrow cells in the study group was lower than that in the control group,while platelet count and hemoglobin were higher.CD3+,CD4+,IFN-γ,and QOL scores were higher than those in the control group,and TNF-α level was lower than that in the control group(P＜0.05).There was no statistically difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Azacitidine combined with Bcl-2 inhibitor venetoclax in the treatment of elderly patients with acute myeloid leukemia can regulate immune function and inflammatory response,improve blood indexes,improve the remission rate of disease,and improve the quality of life,with high safety.
elderly patients with acute myeloid leukemiaazacitidinevenetoclaxcurative effect
万方数据
维普
